IBT, Scripps Win $6.6M to Develop Pan-Ebolavirus Vaccine

06:06 EDT 2 Aug 2017 | Genetic Engineering News

A collaboration between Integrated BioTherapeutics  (IBT) and The Scripps Research Institute (TSRI)  has been awarded a $6.6 million, 5-year grant by the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to develop a vaccine that protects against all ebolaviruses. "This award will enable us to address a pressing global public health need, namely a single vaccine that can protect against all ebolaviruses,” stated IBT’s CSO,  M. Javad Aman, Ph.D., who is co-principal investigator for the collaboration. “To meet this challenge, we have assembled a unique team of experts in immunogen design, structural biology, vaccine development, and animal models of filovirus infection.” Filoviruses, including Ebolavirus , Sudan ebolavirus , Bundibugyo ebolavirus , and Marburg marburgvirus , cause hemorrhagic fever in humans, and infection is lethal in 40% to 90% of cases. The most recent Ebolavirus outbreak in West Africa was caused by the ...

Original Article: IBT, Scripps Win $6.6M to Develop Pan-Ebolavirus Vaccine


More From BioPortfolio on "IBT, Scripps Win $6.6M to Develop Pan-Ebolavirus Vaccine"

Quick Search

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...